AZN: full-year 2020 results
AstraZeneca PLC 11 February 2021 07:00 GMT Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines[1], the Company leveraged its revenue growth to make further progress in profitability, while the strategy of sustainable growth through innovation brought numerous further benefits for patients. AstraZeneca's patient-centric